Home | Find A Doctor | Contact Us

 

RTOG 0813: Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients


Principal Investigator: Andrew Evans, MD
Time frame of study: Ongoing
Location of Study:

Mount Sinai Beth Israel
St.Luke's-Mount Sinai Roosevelt

Contact:

Continuum Cancer Research Program
(212) 844-6286

 

Summary:
The usual treatment for early stage lung cancer is to remove the cancer with surgery. However, some subjects may not be able to have standard surgery.  Subjects who cannot have surgery can receive radiation therapy. The purpose of this study is to determine the maximal tolerated dose of Stereotactic Lung Radiotherapy for centrally-located non-small cell lung cancer and to determine the effectiveness of that dose in subjects who are not able to have surgery.  Stereotactic body radiation therapy (SBRT) is a newer radiation treatment that gives fewer but higher doses of radiation than standard radiation. The higher dose technique may work better to kill cancer cells potentially with fewer side effects than standard radiation therapy. 


Eligibility:

  1. Pathologically (histologically or cytologically) proven diagnosis of non-small cell lung cancer (NSCLC).
  2. Subjects must be considered unable to have surgery for cancer.
  3. Subject must be at least 18 years old
  4. Subjects must have measurable disease

Please call for more information

 

 

Privacy Policy | Site Map
Copyright ©  Icahn School of Medicine at Mount Sinai | Mount Sinai Health System